Pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease.
Pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease. Pulmonx has developed the Zephyr Endobronchial Valve (EBV) Therapy, a non-surgical, investigational approach to treating emphysema. The minimally invasive Zephyr valve is a tiny, one-way valve designed to reduce the volume of the diseased regions of the lung by blocking airflow, in order to improve breathing and increase activity levels. No surgery is involved in the simple, one-hour procedure. More than 25,000 Zephyr valves have been implanted outside the U.S. in the last 10 years. In the United States, Pulmonx is conducting the LIBERATE Clinical Study to evaluate the safety and effectiveness of the Zephyr valve in patients with severe emphysema. Please visit www.pulmonx.com for more information or to find a trial site near you. CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.